ProMIS Neurosciences Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

PMN$3.98-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations


· · For the · · For the · · For the · · For the ·
· · Three Months Ended · · Three Months Ended · · Nine Months Ended · · Nine Months Ended ·
· · September 30, · · September 30, · · September 30, · · September 30, ·
· 2025 · 2024 · 2025 · 2024 ·
Operating expenses:
Research and development	$9,797,418	$2,563,774	$24,011,452	$6,313,373
General and administrative	1,953,014	1,870,903	5,383,737	4,511,660
Total operating expenses	11,750,432	4,434,677	29,395,189	10,825,033
Loss from operations	(11,750,432)	(4,434,677)	(29,395,189)	(10,825,033)

Other income (expense):
Change in fair value of financial instruments	—	16,969,126	—	17,014,080
Interest expense	—	—	—	(76,775)
Other income	170,306	235,912	350,130	399,344
Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE	—	(3,494,536)	—	(3,494,536)
Total other income, net	170,306	13,710,502	350,130	13,842,113

Net (loss) income	$(11,580,126)	$9,275,825	$(29,045,059)	$3,017,080

Net (loss) income per share, basic	$(0.24)	$0.31	$(0.78)	$0.13
Net (loss) income per share, diluted	$(0.24)	$0.31	$(0.78)	$0.13

Weighted-average outstanding Common Shares, basic	48,833,799	30,023,675	37,078,745	22,953,751
Weighted-average outstanding Common Shares, diluted	48,833,799	30,067,095	37,078,745	23,676,104

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.